As the focus in Alzheimer's moves ever more towards treating early disease, there has been a parallel upswing in diagnostics companies and researchers developing blood tests for Alzheimer's disease. O
Research led by UK company Proteome Sciences and King's College London could lead to a clinical blood test for Alzheimer's disease within five years, and, more immediately, could be helpful in selecti
Funding for Proteome Sciences PLC ’s SensiDerm multiplex assay could take the non-animal allergy sensitization test a step closer to validation in the EU, potentially filling a void created by th
The proteomics and peptidomics company Proteome Sciences is looking for pharma company partners to take its novel CK1D inhibitors into the clinic in Alzheimer's disease after achieving in vivo proof